To assess medication expenditure in health systems, Vizient collected data from hospital, non-acute and pediatric care clients for its Pharmacy Market Outlook report. Medications from outsourced compounding pharmacies and 340B purchases were not included.
Here are the No. 1 medications by cost and utilization across eight service lines and therapeutic areas:
Autoimmune and inflammatory diseases: Humira (adalimumab), a medication for rheumatoid arthritis, Crohn’s disease and other conditions
Cardiopulmonary diseases: Trikafta (elexacaftor/tezacaftor/ivacaftor), a cystic fibrosis drug
Endocrine and metabolic diseases: Ozempic (semaglutide), a Type 2 diabetes therapy
Hematological: Eliquis (apixaban), a medicine to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Infectious diseases: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), an HIV-1 infection treatment
Neurology: Ocrevus (ocrelizumab), a multiple sclerosis medication
Oncology: Keytruda (pembrolizumab), a drug approved for more than a dozen cancers
Plasma: Albumin blood test, which helps evaluate for kidney disease and liver disease
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.